Full Breakdown
Legal Battles: Teva vs. Eli Lilly and Live Nation's Antitrust Verdict
4/17/2026, 7:05:23 AM
Teva Pharmaceuticals vs. Eli Lilly: Patent Dispute Revived
On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit revived a patent lawsuit filed by Teva Pharmaceuticals against Eli Lilly concerning their competing migraine drugs, Ajovy and Emgality. This decision overturned a previous ruling by U.S. District Judge Allison Burroughs, who had invalidated Teva's patents and overturned a jury's $176.5 million verdict in favor of Teva. The appellate court found that the patents were valid and sent the case back to federal court in Massachusetts for further proceedings. Teva's lawsuit, initiated in 2018, alleged that Eli Lilly's Emgality infringed on its patents related to Ajovy. Eli Lilly's Emgality generated over $870 million in revenue in 2024, while Ajovy earned Teva $673 million.
Live Nation and Ticketmaster: Antitrust Verdict
In a separate legal matter, a Manhattan federal jury found on April 15, 2026, that Live Nation and its subsidiary, Ticketmaster, illegally maintained monopoly power in the ticketing market. The lawsuit, initiated by the U.S. Department of Justice and numerous state attorneys general, accused Live Nation of engaging in anticompetitive practices that resulted in higher ticket prices for consumers and limited options for artists and venues. The jury's decision followed a five-week trial and revealed that Ticketmaster overcharged concertgoers by $1.72 per ticket at major venues due to its monopolistic behavior. Live Nation's stock fell over 5% following the verdict.
Background of the Case
The lawsuit against Live Nation stemmed from claims that the company used its dominance to restrict competition, including blocking venues from utilizing multiple ticket sellers. Live Nation, which controls approximately 86% of the concert ticketing market, argued that its size was a result of competitive success rather than illegal practices. The company had previously settled with the Justice Department, agreeing to divest some amphitheaters and cap service fees, but many states pursued their own claims, asserting that the settlement did not provide sufficient consumer protections.
Official Statements & Responses
Following the verdict, Jeffrey Kessler, an attorney representing the states, stated, “It’s a great day for antitrust law. It’s a great day for consumers.” California Attorney General Rob Bonta echoed this sentiment, calling the ruling a "historic and resounding victory for artists, fans, and the venues that support them." In contrast, Live Nation's attorney, David Marriott, maintained that the company is not a monopoly and that its practices are legal and competitive.
Criticism & Opposition
Critics of Live Nation's practices have long argued that the company's control over the ticketing market harms consumers and artists alike. During the trial, internal communications from Live Nation executives were revealed, showcasing a dismissive attitude towards customers and pricing practices. This has fueled ongoing discontent among fans and artists, who have historically challenged Ticketmaster's dominance.
What's Next
The legal battles for both Teva Pharmaceuticals and Live Nation are ongoing. Teva's case will return to federal court for further proceedings, while the remedies phase for Live Nation's antitrust case will be determined by U.S. District Judge Arun Subramanian in the coming weeks. The outcomes of these cases could have significant implications for both the pharmaceutical and entertainment industries.
